{"url":"https://newsforagent.com/news/2026-10-28/setpoint-medical-first-boston-procedure","markdown_url":"https://newsforagent.com/news/2026-10-28/setpoint-medical-first-boston-procedure.md","title":"SetPoint Medical Treats First Boston Patient With RA Implant","headline":"SetPoint Medical's Vagus Nerve Implant Used on First Boston Patient at Beth Israel","description":"SetPoint Medical's FDA-approved vagus nerve implant for rheumatoid arthritis reached Boston, where Beth Israel Deaconess treated its first patient.","section":"Product Launches","published_at":"2026-10-28T20:14:02+00:00","modified_at":"2026-10-28T20:14:02+00:00","author":"News Desk","key_takeaways":["Joshua P. Aronson performed the first SetPoint System procedure in Boston at Beth Israel Deaconess Medical Center.","The SetPoint System is the only FDA-approved neuroimmune modulation therapy for adults with moderately to severely active rheumatoid arthritis.","SetPoint Medical raised $140 million in private financing in August 2025 to commercialize the therapy."],"companies":[{"name":"SetPoint Medical","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00002w8/setpoint-medical","website":"http://www.setpointmedical.com"},{"name":"Beth Israel Deaconess Medical Center","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0004mq3/beth-israel-deaconess-medical-center","website":"https://www.bidmc.org"}],"source":{"publisher":"PR Newswire","title":"SetPoint Medical Announces First SetPoint® System Procedure in Boston at Beth Israel Deaconess Medical Center","url":"https://www.prnewswire.com/news-releases/setpoint-medical-announces-first-setpoint-system-procedure-in-boston-at-beth-israel-deaconess-medical-center-302921794.html"},"other_sources":[],"tags":["Product Launches","SetPoint Medical","Beth Israel Deaconess Medical Center"],"body_markdown":"[SetPoint Medical](https://akta.pro/company-profiles/00002w8/setpoint-medical) said the first patient in Boston was treated with its SetPoint System at Beth Israel Deaconess Medical Center, an FDA-approved vagus nerve implant for rheumatoid arthritis. The October 28 announcement from [PR Newswire](https://www.prnewswire.com/news-releases/setpoint-medical-announces-first-setpoint-system-procedure-in-boston-at-beth-israel-deaconess-medical-center-302921794.html) did not disclose the price of the therapy.\n\n## How the Beth Israel Procedure Worked\n\nJoshua P. Aronson, a functional neurosurgeon at [Beth Israel Deaconess Medical Center](https://akta.pro/company-profiles/0004mq3/beth-israel-deaconess-medical-center), performed the procedure. The system pairs a small implantable neurostimulator with targeted stimulation of the left vagus nerve, which the company says activates the body's innate anti-inflammatory pathways tied to rheumatoid arthritis.\n\nThe FDA approval covers adults with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response or intolerance to at least one biologic or targeted synthetic disease-modifying antirheumatic drug. SetPoint says more than 1.5 million Americans live with the disease, which has no cure.\n\n\"An outpatient procedure now opens a fundamentally different treatment pathway for patients with rheumatoid arthritis,\" Aronson said. Brian J. Stout, a rheumatologist at Beth Israel, said neuroimmune modulation \"offers a different mechanism of action for patients whose disease is not managed with initial biological agents.\"\n\nMurthy V. Simhambhatla, SetPoint's president and chief executive, said the company is working with clinicians in the region as access expands across New England. The company also plans to evaluate the platform for multiple sclerosis and Crohn's disease.\n\n## SetPoint's Financing and Reimbursement Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), SetPoint raised $140 million in private financing in August 2025, made up of a $25 million Series C tranche and a $115 million Series D round co-led by Elevage Medical Technologies and Ally Bridge Group. The same records list total funding of $496.4 million and 15 funding rounds.\n\nThe records also show that SetPoint secured CMS Transitional Pass-Through payment status effective January 1, 2026, with a dedicated HCPCS code, C1607, providing incremental hospital outpatient and ambulatory surgery center reimbursement for up to three years.\n\n## Earlier SetPoint System Treatments\n\nOregon Health & Science University became the first Pacific Northwest health system to treat a patient with the SetPoint System, PR Newswire reported in September 2026. In June 2026, Arthritis & Osteoporosis Consultants of the Carolinas treated the first patient in North Carolina with the device, according to PR Newswire.\n\nSetPoint appointed Dan Dearen to its board of directors in October 2026, PR Newswire reported, citing his nearly 40 years of medical device and life sciences leadership.\n\n## SetPoint's Multiple Sclerosis Study\n\nSetPoint enrolled the first patients in April 2026 in a multicenter, randomized, sham-controlled, double-blind pilot study of the system as a potential pro-remyelination therapy for relapsing-remitting multiple sclerosis, according to akta.pro company records. The study is supported by FDA Breakthrough Device Designation and IDE approval and is enrolling up to 60 patients, with sites including the Shepherd Center's Andrew C. Carlos MS Institute, UW Medicine Multiple Sclerosis Center and the Minnesota Center for Multiple Sclerosis.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}